| 001 | 286103 | ||
| 005 | 20240303005728.0 | ||
| 024 | 7 | _ | |a 10.1080/21645515.2023.2289242 |2 doi |
| 024 | 7 | _ | |a pmid:38078840 |2 pmid |
| 024 | 7 | _ | |a 2164-5515 |2 ISSN |
| 024 | 7 | _ | |a 1554-8600 |2 ISSN |
| 024 | 7 | _ | |a 1554-8619 |2 ISSN |
| 024 | 7 | _ | |a 2164-554X |2 ISSN |
| 024 | 7 | _ | |a altmetric:157826420 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02679 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bhatla, Neerja |b 0 |
| 245 | _ | _ | |a Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine. |
| 260 | _ | _ | |a Austin, Tex. |c 2023 |b Landes Bioscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1702390513_9556 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Long-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric study allowed us to compare antibody responses between the younger and older age cohorts at 10-years post-vaccination, and study the impact of initiation of sexual activity and cervical HPV infections on antibody levels. Among the younger (10-14 years) recipients of a single dose, 97.7% and 98.2% had detectable binding antibody titers against HPV 16 and HPV 18 respectively at ten years post-vaccination. The proportions among those receiving a single dose at age 15-18 years were 92.3% and 94.2% against HPV 16 and HPV 18 respectively. Mean HPV 16 binding antibody titers were 2.1 folds (95%CI 1.4 to 3.3) higher in those vaccinated at ages 10-14 years, and 1.9 folds (95%CI 1.2 to 3.0) higher in those vaccinated at 15-18 years compared to mean titers seen in the unvaccinated women. Compared to previous timepoints of 36 or 48 months, binding antibodies against HPV 16 and neutralizing antibodies against both HPV 16 and HPV 18 were significantly higher at 10 years. This rise was more pronounced in participants vaccinated at 15-18 years. No association of marital status or cervical HPV infections was observed with the rise in titer. Durability of antibody response in single dose recipients correlated well with the high efficacy of a single dose against persistent HPV 16/18 infections irrespective of age at vaccination, as we reported earlier. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a HPV |2 Other |
| 650 | _ | 7 | |a Human papillomavirus |2 Other |
| 650 | _ | 7 | |a age-stratified |2 Other |
| 650 | _ | 7 | |a binding antibody |2 Other |
| 650 | _ | 7 | |a neutralizing antibody |2 Other |
| 650 | _ | 7 | |a single dose |2 Other |
| 650 | _ | 7 | |a vaccine |2 Other |
| 700 | 1 | _ | |a Muwonge, Richard |b 1 |
| 700 | 1 | _ | |a Malvi, Sylla G |b 2 |
| 700 | 1 | _ | |a Joshi, Smita |b 3 |
| 700 | 1 | _ | |a Poli, Usha Rani Reddy |b 4 |
| 700 | 1 | _ | |a Lucas, Eric |b 5 |
| 700 | 1 | _ | |a Esmy, Pulikkottil O |b 6 |
| 700 | 1 | _ | |a Verma, Yogesh |b 7 |
| 700 | 1 | _ | |a Shah, Anand |b 8 |
| 700 | 1 | _ | |a Zomawia, Eric |b 9 |
| 700 | 1 | _ | |a Pimple, Sharmila |b 10 |
| 700 | 1 | _ | |a Jayant, Kasturi |b 11 |
| 700 | 1 | _ | |a Hingmire, Sanjay |b 12 |
| 700 | 1 | _ | |a Chiwate, Aruna |b 13 |
| 700 | 1 | _ | |a Vashist, Shachi |b 14 |
| 700 | 1 | _ | |a Mishra, Gauravi |b 15 |
| 700 | 1 | _ | |a Jadhav, Radhika |b 16 |
| 700 | 1 | _ | |a Siddiqi, Maqsood |b 17 |
| 700 | 1 | _ | |a Anantharaman, Devasena |b 18 |
| 700 | 1 | _ | |a Panicker, Gitika |b 19 |
| 700 | 1 | _ | |a Butt, Julia |0 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |b 20 |u dkfz |
| 700 | 1 | _ | |a Sankaran, Subha |b 21 |
| 700 | 1 | _ | |a Kannan, Thiraviam Pillai Rameshwari Ammal |b 22 |
| 700 | 1 | _ | |a Varghese, Rintu |b 23 |
| 700 | 1 | _ | |a Kartha, Purnima |b 24 |
| 700 | 1 | _ | |a Pillai, M Radhakrishna |b 25 |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 26 |u dkfz |
| 700 | 1 | _ | |a Müller, Martin |0 P:(DE-He78)41d8b55dd01aace350f81d031f9f707f |b 27 |
| 700 | 1 | _ | |a Sehr, Peter |0 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1 |b 28 |u dkfz |
| 700 | 1 | _ | |a Unger, Elizabeth R |b 29 |
| 700 | 1 | _ | |a Sankaranarayanan, Rengaswamy |b 30 |
| 700 | 1 | _ | |a Basu, Partha |0 0000-0003-0124-4050 |b 31 |
| 773 | _ | _ | |a 10.1080/21645515.2023.2289242 |g Vol. 19, no. 3, p. 2289242 |0 PERI:(DE-600)2664177-X |n 3 |p 2289242 |t Human vaccines & immunotherapeutics |v 19 |y 2023 |x 2164-5515 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:286103 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)41d8b55dd01aace350f81d031f9f707f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)219d54a7bf634121fbf16bea82d434e1 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HUM VACC IMMUNOTHER : 2022 |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-07-18T15:23:36Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-07-18T15:23:36Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-07-18T15:23:36Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-28 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-28 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-28 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-28 |
| 920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Infektionen und Krebs-Epidemiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)W040-20160331 |k W040 |l Gruppe Sehr EMBL |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W040-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::